PFE News & Events

Pfizer announced positive topline results from a Phase 2 study investigating tilrekimig in adults with moderate to severe atopic dermatitis. The study met its primary efficacy endpoint, demonstrating a statistically significant increase in the percentage of participants achieving EASI-75 at Week 16, compared to placebo. In Stage 2 of the study, which evaluated monthly dosing regimens, tilrekimig showed competitive efficacy. The placebo-adjusted percentage of participants achieving EASI-75 at Week 16 was: 38.7% for the low tested dose; 51.9% for the middle tested dose; and 49.4% for the high tested dose. The two highest dose levels tested with tilrekimig strongly suggest potentially meaningful improvements to approved standard of care biologics. Tilrekimig is an investigational trispecific antibody that simultaneously targets interleukin-4, interleukin-13, and thymic stromal lymphopoietin, with the potential to be a once-monthly treatment option for multiple chronic inflammatory conditions driven by an overactive Type 2 immune response, without affecting receptors on healthy cells. "We are encouraged by the topline Phase 2 results for tilrekimig, which show that combining the potent inhibition of IL-4/13 and TSLP pathways has the potential to deliver improved efficacy over the standard of care for atopic dermatitis," said Mike Vincent, Chief Inflammation & Immunology Officer at Pfizer. "We plan to advance a broad clinical development program for tilrekimig, a potential first-in-class trispecific antibody discovered at Pfizer, in atopic dermatitis and other Th2-mediated inflammatory diseases including asthma and COPD."

Catch up on the weekend's top five stories with this list compiled by The Fly: 1) KKR (KKR) is working on a sale of CoolIT Systems, hoping to fetch a price tag in excess of $3B, Oliver Barnes and Antoine Gara of The Financial Times reports, citing people familiar with the matter. This is a massive increase from the unit's $270M valuation when KKR bought a majority stake in 2023. 2) Dr. Vinay Prasad, who issued several controversial decisions, including having refused to accept Moderna's (MRNA) application for a new mRNA flu vaccine and refused an application for a Huntington's drug's review from UniQure (QURE), is leaving the agency at the end of April, reported The New York Times' Christina Jewett on Friday evening, citing a Health and Human Services spokesman. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Biotech stocks that could be impacted by the news include Sarepta (SRPT), Xencor (XNCR), PTC Therapeutics (PTCT), Biohaven (BHVN), Edgewise Therapeutics (EWTX), Design Therapeutics (DSGN), Ultragenyx (RARE), Avidity Biosciences (RNA), Dyne Therapeutics (DYN), Wave Life Sciences (WVE), MeiraGTx (MGTX), uniQure (QURE), Regenxbio (RGNX), Moderna (MRNA), Novavax (NVAX) and Lexeo Therapeutics (LXEO). 3) Plug Power (PLUG) plans to offer hydrogen electricity, as much as 250 megawatts, in an auction President Donald Trump is eager to make happen later this year, Will Wade and Naureen Malik of Bloomberg reports, citing chairman Andy Marsh. PJM Interconnection, which is facing power shortages due to surging consumption by data centers to power AI, has been urged by the Trump administration to hold an emergency auction to bolster supplies. 4) Prudential (PRU) disclosed yesterday that on March 6, the Prudential Gibraltar Financial Life Insurance Co., a subsidiary of Prudential Financial, issued a press release in Japan reporting instances of the unauthorized removal of information by certain employees of PGFL seconded to financial institutions in Japan. The investigation confirmed that 11 employees in total removed 379 instances of information at seven contracted agencies. The removed information pertained to operational matters such as sales performance at the assigned agencies. "After confirming the content of all cases with the agencies, no issues were identified that would raise concerns under the Unfair Competition Prevention Act, nor was there any inappropriate removal of contract information," Prudential Gibraltar Financial said. 5) Activist investor Starboard Value has built a stake in Lamb Weston (LW) and has been pushing to company to speed up improvements and cost cutting to boost stock performance, Lauren Thomas of The Wall Street Journal reports, citing people familiar with the matter. Starboard is now one of the largest shareholders in the company, the sources added.

Dr. Vinay Prasad, who issued several controversial decisions, including having refused to accept Moderna's (MRNA) application for a new mRNA flu vaccine and refused an application for a Huntington's drug's review from UniQure (QURE), is leaving the agency at the end of April, reported The New York Times' Christina Jewett on Friday evening, citing a Health and Human Services spokesman. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Biotech stocks that could be impacted by the news include Sarepta (SRPT), Xencor (XNCR), PTC Therapeutics (PTCT), Biohaven (BHVN), Edgewise Therapeutics (EWTX), Design Therapeutics (DSGN), Ultragenyx (RARE), Avidity Biosciences (RNA), Dyne Therapeutics (DYN), Wave Life Sciences (WVE), MeiraGTx (MGTX), uniQure (QURE), Regenxbio (RGNX), Moderna (MRNA), Novavax (NVAX) and Lexeo Therapeutics (LXEO).

Stocks had a down Friday to close out a down week after data showed unexpected job cuts and rising unemployment in February. Nonfarm payrolls fell by 92,000 in February, missing the growth of 55,000 that economists predicted, and the unemployment rate rose to 4.4% from 4.3%. Meanwhile, West Texas Intermediate futures broke above $90 per barrel for first time since October 2023 after President Donald Trump said in a Truth Social post that there won't be a deal to end the U.S.-Iran war without an "unconditional surrender."Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:President Trump and Secretary Hegseth met with the CEOs of defense companies today at the White House asthere "will be no deal with Iran except unconditional surrender"Marvellreceived a pair of upgrades and a number of price target hikes from Wall Street firms after itswere strongJPMorgan says Costco's"core story remains intact" following the membership club retailer'sGapshares traded lower after Old Navy and Athletain Q4Day One Biopharmaceuticalsby Servier for $21.50 per share in cash2. WALL STREET CALLS:Marvellwasto Buy at Benchmark and BofA on expectations for accelerating data center demandKarmanto Overweight at Piper SandlerOktato Outperform at BMO CapitalWedbushTrade Deskto Underperform, says impact of OpenAI partnership overestimatedZoetisto Hold from Buy at Nephron Research3. AROUND THE WEB:China near deal to order 500 Boeing737 Max jets, Bloomberg saysStates preparing to challenge planned tie-up of Nexstarwith Tegna, WSJ reportsPrivate equity firms including Blackstoneand TPGhave expressed interest in acquiring Whitestone REIT, Reuters reportsChina has approved Pfizer'sGLP-1 treatment Xianweiying for weight management in adults, Reuters saysMetahired the engineering team from Atma Sciences, the startup that makes the vibe coding app Gizmo, earlier in 2026 to join its Superintelligence Labs, Business Insider reports4. MOVERS:Samsaragained after reportingand providing guidance for Q1 and FY27ASP Isotopesincreased afterQuantum Leap Energy has entered into a non-binding MOU with a large publicly traded U.S. energy companyWestern Alliancedeclined after beingby Jefferies (JEF) that payments of $126.4M owed to the bank pursuant to a forbearance agreement will not be paid as agreedREalloysfell after announcing a 2.7MIngram Microdeclined after announcing a 8.999M5. EARNINGS/GUIDANCE:Algonquin Powersreportedand backed its guidance for FY26Embraerreported, with revenue beating consensusImmuneeringreported, with CEO Ben Zeskind commenting that 2025 was "a transformative year"SunCar Technologyreportedfor Q4Methode Electronicsreported Q3 results andfor FY26INDEXES:The Dow fell 0.95%, or 453.19, to 47,501.55, the Nasdaq lost 1.59%, or 361.31, to 22,387.68, and the S&P 500 declined 1.33%, or 90.69, to 6,740.02.